carmustine has been researched along with Syndrome in 8 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen." | 7.71 | Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. ( Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G, 2001) |
| "Delayed pulmonary toxicity syndrome, characterized by interstitial pneumonia and pulmonary fibrosis, is common following high-dose bischloroethylnitrosourea (BCNU) (carmustine, [1,3-bis (2-chloroethyl)-1-nitrosourea]) containing chemotherapeutic regimens." | 3.72 | Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids. ( Brown, KK; Cool, CD; Jones, RB; Lynch, DA; Suratt, BT, 2003) |
| "Our aim was to describe the incidence, clinical course, and risk factors for idiopathic pneumonia syndrome (IPS) after high-dose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by autologous stem cell transplantation for high-risk breast cancer." | 3.72 | Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. ( Champlin, RE; Giralt, SA; Rondon, G; Saliba, RM; Shannon, VR; Ueno, NT; Wong, R, 2003) |
| "We report on three patients with multiple myeloma who developed drug-induced pneumonitis 1-2(1/2) months following maintenance (post autologous transplantation) chemotherapy with CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) and 6-20 months after exposure to carmustine (BCNU) 300 mg/m(2), used in combination with melphalan 140 mg/m(2), as pre-transplant conditioning regimen." | 3.71 | Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy. ( Cottler-Fox, M; Fassas, A; Gojo, I; Meisenberg, B; Papadimitriou, JC; Rapoport, A; Tricot, G, 2001) |
| "The incidence of PTS in breast cancer patients treated with a BCNU-containing HDC regimen can be remarkably high." | 1.31 | Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation. ( Blume, KG; Cao, TM; Hu, WW; Johnston, LJ; Negrin, RS; Rizk, NW; Shizuru, JA; Stockerl-Goldstein, KE; Taylor, TL; Wong, RM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavolé, J | 1 |
| Le Goff, M | 1 |
| Oudjit, A | 1 |
| Sogni, P | 1 |
| Mallet, V | 1 |
| Suratt, BT | 1 |
| Lynch, DA | 1 |
| Cool, CD | 1 |
| Jones, RB | 1 |
| Brown, KK | 1 |
| Wong, R | 1 |
| Rondon, G | 1 |
| Saliba, RM | 1 |
| Shannon, VR | 1 |
| Giralt, SA | 1 |
| Champlin, RE | 1 |
| Ueno, NT | 1 |
| Gomez, GA | 1 |
| Aggarwal, KK | 1 |
| Han, T | 1 |
| Rubio, C | 1 |
| Hill, ME | 1 |
| Milan, S | 1 |
| O'Brien, ME | 1 |
| Cunningham, D | 1 |
| Cao, TM | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, KE | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Taylor, TL | 1 |
| Rizk, NW | 1 |
| Wong, RM | 1 |
| Blume, KG | 1 |
| Hu, WW | 1 |
| Fassas, A | 1 |
| Gojo, I | 1 |
| Rapoport, A | 1 |
| Cottler-Fox, M | 1 |
| Meisenberg, B | 1 |
| Papadimitriou, JC | 1 |
| Tricot, G | 1 |
| Schuler, D | 1 |
| Koós, R | 1 |
| Krauze, I | 1 |
| Péter, A | 1 |
1 trial available for carmustine and Syndrome
| Article | Year |
|---|---|
Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug | 1982 |
7 other studies available for carmustine and Syndrome
| Article | Year |
|---|---|
Abdominal computed tomography angiography in post-transplantation sinusoidal obstruction syndrome associated with R-DHAOX/BEAM toxicity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Computed Tomography Angiography; C | 2018 |
Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2003 |
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cyclophosphamid | 2003 |
Idiopathic pneumonia syndrome after high-dose chemotherapy for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Carmustine; Female; Hodgkin Disease; Humans; M | 1997 |
Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2000 |
Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Thera | 2001 |
Paraneoplastic syndrome in childhood.
Topics: Brain Diseases; Carmustine; Child, Preschool; Humans; Lomustine; Male; Mediastinal Neoplasms; Methot | 1977 |